Mantle Cell Lymphoma

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the toxicities related to stem cell transplantation for patients with mantle cell lymphoma (MCL).

Long-term results from the Nordic MCL2 and MCL3 trials showed patients with mantle cell lymphoma who are positive for minimal residual disease following allogenic stem cell transplant had significantly shorter survival.

John P. Leonard, MD, professor of Medicine at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses some of the exciting advancements taking place in the field of mantle cell lymphoma (MCL).

The FDA has granted a priority review to a new drug application for acalabrutinib for patients with previously-treated mantle cell lymphoma.

The FDA has granted acalabrutinib a breakthrough therapy designation for patients with previously-treated mantle cell lymphoma.

Grzegorz S. Nowakowski, MD, assistant professor of medicine at Mayo Clinic, discusses what potential immunotherapy agents have in the treatment landscape of mantle cell lymphoma (MCL).

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses some of the emerging developments on the horizon in mantle cell lymphoma (MCL).

Five-year follow-up from the BRIGHT study confirmed that bendamustine plus rituximab is associated with improved progression-free survival compared with R-CHOP or R-CVP in patients with mantle cell lymphoma or indolent non-Hodgkin lymphoma.

Phase III results from the RAY trial showed that patients with mantle cell lymphoma treated with ibrutinib (Imbruvica) had superior quality of life compared with patients treated with temsirolimus.

Christian Winther Eskelund, MD, discusses TP53 mutations in mantle cell lymphoma.

Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses the toxicities of the phase II and phase III studies investigating the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with mantle cell lymphoma (MCL).

Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses TP53-mutated mantle cell lymphoma (MCL).

Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses a study of TP53 mutations in mantle cell lymphoma.

Connie Batlevi, MD, PhD, discusses the combination of ibrutinib and buparlisib in MCL.